NCT00310180 - TAILORx - Hormone Therapy (tamoxifen, anastrazole, letrozole, exemestane) + Chemotherapy vs Hormone Therapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer

In patients with a recurrence score (RS) of 11 to 25 on the Oncotype DX Breast Recurrence Score assay, chemotherapy did not improve invasive disease–free survival (iDFS) when added to adjuvant ET. Almost two-thirds of the more than 10,000 patients enrolled in the study had a midrange RS of 11 to 25, Joseph A. Sparano, MD, of Montefiore Medical Center, who presented the study results, said. ASCO 2018